A detailed history of Carson Advisory Inc. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Carson Advisory Inc. holds 24,570 shares of ZNTL stock, worth $73,710. This represents 0.06% of its overall portfolio holdings.

Number of Shares
24,570
Previous 15,770 55.8%
Holding current value
$73,710
Previous $64,000 40.63%
% of portfolio
0.06%
Previous 0.05%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$2.9 - $4.57 $25,520 - $40,216
8,800 Added 55.8%
24,570 $90,000
Q2 2024

Aug 07, 2024

BUY
$4.09 - $16.13 $12,270 - $48,390
3,000 Added 23.49%
15,770 $64,000
Q1 2024

May 03, 2024

BUY
$10.83 - $16.49 $138,299 - $210,577
12,770 New
12,770 $201,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Carson Advisory Inc. Portfolio

Follow Carson Advisory Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carson Advisory Inc., based on Form 13F filings with the SEC.

News

Stay updated on Carson Advisory Inc. with notifications on news.